GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (STU:APE1) » Definitions » Cyclically Adjusted Price-to-FCF

Addex Therapeutics (STU:APE1) Cyclically Adjusted Price-to-FCF : (As of Jan. 18, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Addex Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Addex Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Addex Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics Cyclically Adjusted Price-to-FCF Chart

Addex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Addex Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Addex Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Addex Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Addex Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Addex Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Addex Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.303/107.4679*107.4679
=-0.303

Current CPI (Sep. 2024) = 107.4679.

Addex Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201012 0.000 102.138 0.000
201106 0.000 102.678 0.000
201112 0.000 101.408 0.000
201206 0.000 101.596 0.000
201212 0.000 100.968 0.000
201306 0.000 101.466 0.000
201312 0.000 101.036 0.000
201406 0.000 101.517 0.000
201412 0.000 100.704 0.000
201506 0.000 100.464 0.000
201512 0.000 99.386 0.000
201606 0.000 100.088 0.000
201612 0.000 99.380 0.000
201706 0.000 100.285 0.000
201712 0.000 100.213 0.000
201806 0.000 101.435 0.000
201812 0.000 100.906 0.000
201903 -10.323 101.571 -10.922
201906 -8.436 102.044 -8.884
201909 -20.294 101.396 -21.509
201912 0.081 101.063 0.086
202003 -17.716 101.048 -18.842
202006 -25.941 100.743 -27.673
202009 -10.698 100.585 -11.430
202012 2.726 100.241 2.923
202103 -8.978 100.800 -9.572
202106 -20.778 101.352 -22.032
202109 -8.243 101.533 -8.725
202112 -9.838 101.776 -10.388
202203 -14.978 103.205 -15.597
202206 -18.221 104.783 -18.688
202209 -7.013 104.835 -7.189
202212 -6.554 104.666 -6.729
202303 -4.673 106.245 -4.727
202306 -2.111 106.576 -2.129
202309 -1.652 106.570 -1.666
202312 -0.635 106.461 -0.641
202403 -2.795 107.355 -2.798
202406 -2.047 107.991 -2.037
202409 -0.303 107.468 -0.303

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Addex Therapeutics  (STU:APE1) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Addex Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Addex Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
Chemin des Mines 9, Geneva, CHE, 1202
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Addex Therapeutics Headlines

No Headlines